Lexaria Bioscience Corp (LEXX)

$0.56 -0.06 (-9.68%)
Market Cap 13.78M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 1,457,900
Avg Vol 677,384
Day's Range N/A - N/A
Shares Out 22.23M
Stochastic %K 8%
Beta 0.63
Analysts Strong Sell
Price Target $5.33

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Mralwaysgreen
Mralwaysgreen Dec. 25 at 7:58 PM
$LEXX happy holidays all! Oh, btw boston guy, I was joking last time. You actually share gems with us. Besides that, you’re always coming from an different angle which is hightly contributing.
0 · Reply
ttolmani2
ttolmani2 Dec. 25 at 2:24 PM
$LEXX
0 · Reply
Gashcooper
Gashcooper Dec. 25 at 4:08 AM
$LEXX https://www.benzinga.com/news/health-care/25/12/49566831/lexaria-says-oral-glp-1-cuts-side-effects-nearly-50-versus-novo-nordisks-rybelsus
1 · Reply
The_Wealth_Maker
The_Wealth_Maker Dec. 24 at 10:38 PM
$LEXX Seriously, thank you Boston7452 for all the insight and infos you give us. 👍🏾💯
0 · Reply
Boston7452
Boston7452 Dec. 24 at 10:21 PM
$LEXX Well said ⬇️
0 · Reply
Boston7452
Boston7452 Dec. 24 at 8:43 PM
$LEXX Actually its odd no one other than me is really talking about it. If a topic is avoided on these types of forums, for the most part, with the company making efforts in the area, its a topic worth digging into further to see why its not being discussed.
1 · Reply
Mralwaysgreen
Mralwaysgreen Dec. 24 at 8:13 PM
$LEXX boston is a crazy guy. I finally understand why he always talks about cbd and marihuana
1 · Reply
Boston7452
Boston7452 Dec. 24 at 7:29 PM
$LEXX What will change if the US reclassifies marijuana? "The reclassification will make it easier for researchers to obtain funding for clinical trials and for pharmaceutical companies to apply for FDA approval. As a result of its Schedule I status, bureaucratic and financial hurdles have largely kept drug companies from conducting the clinical trials necessary for regulatory approval of new marijuana-derived drugs."
1 · Reply
hovian
hovian Dec. 24 at 5:49 PM
$LEXX if go .65c will escalate to .75c bcz of cover
0 · Reply
hovian
hovian Dec. 24 at 5:47 PM
$LEXX short interest yesterday...
0 · Reply
Latest News on LEXX
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Dec 23, 2025, 12:06 PM EST - 2 days ago

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

NVO

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 2 days ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:00 PM EST - 8 days ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 10 days ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 6 weeks ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 2 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 3 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 3 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 3 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 4 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 4 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 5 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 5 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 5 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 5 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 6 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 7 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 7 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 8 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 8 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 8 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 8 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 9 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 9 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 10 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 10 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 11 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 11 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 11 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Releases Annual Letter from the CEO

Jan 30, 2025, 9:15 AM EST - 11 months ago

Lexaria Releases Annual Letter from the CEO

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

Oct 8, 2024, 9:20 AM EDT - 1 year ago

Lexaria Updates Current GLP-1 Market

Mralwaysgreen
Mralwaysgreen Dec. 25 at 7:58 PM
$LEXX happy holidays all! Oh, btw boston guy, I was joking last time. You actually share gems with us. Besides that, you’re always coming from an different angle which is hightly contributing.
0 · Reply
ttolmani2
ttolmani2 Dec. 25 at 2:24 PM
$LEXX
0 · Reply
Gashcooper
Gashcooper Dec. 25 at 4:08 AM
$LEXX https://www.benzinga.com/news/health-care/25/12/49566831/lexaria-says-oral-glp-1-cuts-side-effects-nearly-50-versus-novo-nordisks-rybelsus
1 · Reply
The_Wealth_Maker
The_Wealth_Maker Dec. 24 at 10:38 PM
$LEXX Seriously, thank you Boston7452 for all the insight and infos you give us. 👍🏾💯
0 · Reply
Boston7452
Boston7452 Dec. 24 at 10:21 PM
$LEXX Well said ⬇️
0 · Reply
Boston7452
Boston7452 Dec. 24 at 8:43 PM
$LEXX Actually its odd no one other than me is really talking about it. If a topic is avoided on these types of forums, for the most part, with the company making efforts in the area, its a topic worth digging into further to see why its not being discussed.
1 · Reply
Mralwaysgreen
Mralwaysgreen Dec. 24 at 8:13 PM
$LEXX boston is a crazy guy. I finally understand why he always talks about cbd and marihuana
1 · Reply
Boston7452
Boston7452 Dec. 24 at 7:29 PM
$LEXX What will change if the US reclassifies marijuana? "The reclassification will make it easier for researchers to obtain funding for clinical trials and for pharmaceutical companies to apply for FDA approval. As a result of its Schedule I status, bureaucratic and financial hurdles have largely kept drug companies from conducting the clinical trials necessary for regulatory approval of new marijuana-derived drugs."
1 · Reply
hovian
hovian Dec. 24 at 5:49 PM
$LEXX if go .65c will escalate to .75c bcz of cover
0 · Reply
hovian
hovian Dec. 24 at 5:47 PM
$LEXX short interest yesterday...
0 · Reply
LongLEXX
LongLEXX Dec. 24 at 5:37 PM
$LEXX Time to rethink those shorts!
0 · Reply
LongLEXX
LongLEXX Dec. 24 at 4:48 PM
$LEXX Now that the Ph1b results are showing their strengths there is every reason to believe other companies besides our PharmaCO interest are taking notice of our achievements and chatting up Rich and the gang to create new relationships and perhaps future partnerships. Maybe we won't have to wait until April for partnership news. This is the nature of publicly owned companies is sometimes you don't know what's coming down the pipe until it pops up in your news feed one morning. Are you really listening shorts?
2 · Reply
Heaps
Heaps Dec. 24 at 4:35 PM
$LEXX a very Merry Christmas Bunka and co. For all investors rocks and coal!
1 · Reply
Boston7452
Boston7452 Dec. 24 at 3:58 PM
$LEXX "GLP-1-H24-4 Australian study has two arms that include CBD formulations. The results from these studies can show a great deal of info regarding the safety and efficacy of DHT/CBD formulations in a clinical setting. This information can be used in further clinical studies with DHT/CBD whether the studies are for Hypertension, Diabetes, Dementia and or GLP-1 indications etc. "
0 · Reply
TheRealStockRocket
TheRealStockRocket Dec. 24 at 3:55 PM
$LEXX 100% planned short attack at the open....This can be an epic squeeze of all squeezes....The data that came out was terrific and undeniable. ...more data next week as promised in PR. Collecting as much as I can at these Santa Claus gift prices .
1 · Reply
Boston7452
Boston7452 Dec. 24 at 3:30 PM
$LEXX Epidiolex Composition suggests they combined Epidiolex with Dtech in that patent. "Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy"
1 · Reply
paolo73
paolo73 Dec. 24 at 3:21 PM
$LEXX My only hope is that these idiots bring the title back to 0.85/0.9 so as to come out on top and screw this idiot company....
1 · Reply
lem0ntr33
lem0ntr33 Dec. 24 at 3:19 PM
$LEXX holders
1 · Reply
Boston7452
Boston7452 Dec. 24 at 3:15 PM
$LEXX https://lexariabioscience.com/2023/01/23/former-president-of-gw-pharmaceuticals-usa-joins-lexaria-bioscience-as-strategic-advisor/
0 · Reply
GaryGherkins
GaryGherkins Dec. 24 at 3:14 PM
$LEXX this management team got things backwards. first you release the positive news when the stock was up near $1.50 & sell shares into the volume uptick with an atm. these knuckleheads do a financing deal near highs with no pr backup & the stock gets dismantled & is basically ruined until the next reverse split.
1 · Reply
frchmn
frchmn Dec. 24 at 3:11 PM
$LEXX out for now. stop loss hit at .57.
0 · Reply
Boston7452
Boston7452 Dec. 24 at 3:09 PM
$LEXX "On December 18, 2025, President Trump signed an executive order, "Increasing Medical Marijuana and Cannabidiol Research," that directs federal agencies to expedite the rescheduling of marijuana and aims to improve access to CBD products"
0 · Reply